• Wortmannin: Precision PI3K Inhibitor for Advanced Assays

  2026-06-10

  Wortmannin, a selective and irreversible PI3K inhibitor, empowers researchers to dissect PI3K/Akt/mTOR signaling with unmatched specificity in cancer, autophagy, and host-pathogen studies. This guide delivers actionable workflows, optimization strategies, and new mechanistic insights from recent advances.

• Ruxolitinib Triggers Mitochondrial Apoptosis in Anaplastic T

  2026-06-10

  The reference study demonstrates that ruxolitinib, a JAK1/2 inhibitor, induces both apoptosis and pyroptosis in anaplastic thyroid carcinoma (ATC) cells by transcriptionally inhibiting DRP1-mediated mitochondrial fission. This mechanistic insight identifies a novel therapeutic vulnerability in highly aggressive ATC and guides mitochondrial membrane potential assay design for apoptosis research.

• Metoprolol Tartrate in Cardiovascular Research: Advanced App

  2026-06-09

  Metoprolol Tartrate, a selective β1-adrenergic blocking agent from APExBIO, empowers cardiovascular and transplantation research with high specificity and reproducible results. Recent findings reveal its unique benefit in post-transplant hematopoietic recovery workflows, setting it apart from nonselective β-blockers.

• Metronidazole in OAT3 Inhibition and Microbiota Research

  2026-06-09

  Metronidazole delivers unique capabilities as both a nitroimidazole antibiotic and a potent OAT3 inhibitor, making it crucial in drug-drug interaction and gut-immune modulation studies. This article translates recent experimental breakthroughs into actionable protocols, offering troubleshooting guidance for precision research workflows.

• Protease Inhibitor Cocktail EDTA-Free: Optimizing Sensitive

  2026-06-08

  APExBIO’s Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) empowers researchers to extract and analyze proteins with unrivaled integrity, even in phosphorylation-sensitive and complex multi-omics workflows. Its robust, EDTA-free formulation provides reliable inhibition across protease classes, streamlining experimental success from bench to translational breast cancer research.

• ALDH2 Activation Promotes Cardiomyocyte Proliferation in Hea

  2026-06-08

  Recent research demonstrates that activation of ALDH2 in mice substantially extends the proliferative window of cardiomyocytes, offering a promising approach to delay or mitigate heart failure caused by ventricular pressure overload. These findings highlight the therapeutic potential of ALDH2 activators for cardiac regeneration and underscore opportunities for advanced cardiac ischemia research.

• β-Elemene: Applied Workflows for Adipogenesis and Neuroprote

  2026-06-07

  β-Elemene offers a rare dual-action profile—modulating adipogenesis and supporting neuroprotection—making it indispensable for advanced metabolic and neural research. This article translates the latest bench findings into stepwise, data-driven workflows, troubleshooting strategies, and practical guidance for maximizing reproducibility with APExBIO's β-Elemene.

• Triamcinolone (B1859): Technical Guidance for Glucocorticoid

  2026-06-06

  Triamcinolone is a synthetic glucocorticoid agonist designed for controlled studies of glucocorticoid signaling, inflammation, and immunosuppression. It addresses the need for high-purity, research-grade reagents with reliable solubility and stability profiles. This compound is strictly for research use and is not appropriate for diagnostic or clinical applications.

• Repurposing FDA-Approved Drugs to Modulate CRISPR DNA Repair

  2026-06-05

  This study systematically screens over 7,000 clinically approved drugs to identify modulators of DNA double-strand break (DSB) repair pathway choice during CRISPR genome editing in human induced pluripotent stem cells. The work reveals new opportunities for enhancing gene editing precision and synthetic lethality-based therapies by pharmacologically biasing cellular repair mechanisms.

• LLY-507: Redefining SMYD2 Inhibition in Translational Oncolo

  2026-06-05

  Explore how LLY-507, a potent and selective SMYD2 inhibitor from APExBIO, is setting new standards in mechanistic cancer and fibrosis research. This article merges the latest biological insights, preclinical validation, and translational strategy, providing researchers with actionable guidance for integrating LLY-507 into advanced oncology and fibrosis workflows. Building upon recent literature and protocol innovations, it uniquely addresses the bridge between epigenetic regulation and clinical relevance.

• (S)-(+)-Ibuprofen: COX Inhibitor Workflows and Troubleshooti

  2026-06-04

  (S)-(+)-Ibuprofen, the pharmacologically active enantiomer, offers precise COX-2 selectivity for high-impact inflammation pathway research. This guide details experimental workflows, protocol enhancements, and troubleshooting strategies for bench and translational studies, leveraging APExBIO’s high-purity reagent.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-06-04

  Wang et al. reveal that the METTL16-SENP3-LTF signaling axis confers ferroptosis resistance and promotes tumor progression in hepatocellular carcinoma (HCC). This mechanistic insight highlights new therapeutic opportunities for sensitizing HCC to ferroptosis by targeting iron homeostasis pathways.

• Baicalin Methyl Ester Restores Intestinal Barrier via P65/TN

  2026-06-03

  This study demonstrates that baicalin methyl ester (BME) effectively prevents LPS-induced damage to the intestinal barrier in mice and MODE-K cells by modulating the P65/TNF-α/MLCK/ZO-1 signaling pathway. The findings provide mechanistic insights into BME's role in preserving tight junction integrity and highlight implications for translational research on mucosal inflammation.

• PXR Activation by Pregnenolone-16α-carbonitrile Attenuates C

  2026-06-03

  This study reveals that activation of the pregnane X receptor (PXR) by pregnenolone-16α-carbonitrile (PCN) protects against cholestatic liver injury by inhibiting both canonical and non-canonical pyroptosis in hepatocytes. The findings highlight a novel gene regulatory mechanism and position PXR as a promising therapeutic target in cholestatic liver disease.

• Strategic ROS Sensing: 2',7'-Dichlorofluorescein Diacetate i

  2026-06-02

  This article offers a thought-leadership perspective for translational researchers on the mechanistic, experimental, and strategic dimensions of intracellular reactive oxygen species (ROS) detection using 2',7'-Dichlorofluorescein diacetate. By synthesizing recent advances in post-stroke inflammation, oncology, and nanocarrier-enabled drug delivery, we highlight how emerging applications and optimized workflows can transform the role of fluorogenic ROS probes for biomedical innovation.

449 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page